Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
There is no change in the price for Pacira Pharmaceuticals today.
Pacira Pharmaceuticals is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
As a result the target price of 29 € shows a very positive potential of 63.84% compared to the current price of 17.7 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 0.000% | -13.235% | -20.270% | -15.714% | -18.056% | -47.633% | -70.500% |
| Rockwell Medical Inc. | -0.860% | 0.560% | 11.997% | -60.222% | 19.364% | -52.778% | -92.353% |
| Twist Bioscience Corp | 1.240% | 17.583% | 34.806% | -19.771% | 28.223% | 49.009% | -76.351% |
| Vericel Corp. | -0.600% | -0.602% | 8.553% | -38.318% | 4.430% | 26.631% | 4.265% |
Comments
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat